Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 27310 | 191 | 45.2 | 94% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | TPL2 | Author keyword | 19 | 80% | 6% | 12 |
| 2 | TPL 2 | Author keyword | 14 | 100% | 4% | 7 |
| 3 | TPL2 KINASE | Author keyword | 8 | 100% | 3% | 5 |
| 4 | TUMOR PROGRESSION LOCUS 2 | Author keyword | 6 | 80% | 2% | 4 |
| 5 | MAP3K8 | Author keyword | 6 | 58% | 4% | 7 |
| 6 | COT TPL2 | Author keyword | 6 | 100% | 2% | 4 |
| 7 | TP12 | Author keyword | 6 | 100% | 2% | 4 |
| 8 | COT | Author keyword | 5 | 30% | 7% | 13 |
| 9 | INFLAMMAT SIGNALING | Address | 4 | 75% | 2% | 3 |
| 10 | MAP3 KINASE | Author keyword | 2 | 67% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | TPL2 | 19 | 80% | 6% | 12 | Search TPL2 | Search TPL2 |
| 2 | TPL 2 | 14 | 100% | 4% | 7 | Search TPL+2 | Search TPL+2 |
| 3 | TPL2 KINASE | 8 | 100% | 3% | 5 | Search TPL2+KINASE | Search TPL2+KINASE |
| 4 | TUMOR PROGRESSION LOCUS 2 | 6 | 80% | 2% | 4 | Search TUMOR+PROGRESSION+LOCUS+2 | Search TUMOR+PROGRESSION+LOCUS+2 |
| 5 | MAP3K8 | 6 | 58% | 4% | 7 | Search MAP3K8 | Search MAP3K8 |
| 6 | COT TPL2 | 6 | 100% | 2% | 4 | Search COT+TPL2 | Search COT+TPL2 |
| 7 | TP12 | 6 | 100% | 2% | 4 | Search TP12 | Search TP12 |
| 8 | COT | 5 | 30% | 7% | 13 | Search COT | Search COT |
| 9 | MAP3 KINASE | 2 | 67% | 1% | 2 | Search MAP3+KINASE | Search MAP3+KINASE |
| 10 | CANCER OSAKA THYROID COT | 1 | 100% | 1% | 2 | Search CANCER+OSAKA+THYROID+COT | Search CANCER+OSAKA+THYROID+COT |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NF KAPPA B1 P105 | 38 | 60% | 22% | 42 |
| 2 | TPL 2 | 38 | 84% | 11% | 21 |
| 3 | ACTIVATE ERK | 24 | 91% | 5% | 10 |
| 4 | TPL2 ACTIVATION | 20 | 100% | 5% | 9 |
| 5 | TPL2 KINASE | 12 | 75% | 5% | 9 |
| 6 | LIPOPOLYSACCHARIDE ACTIVATION | 11 | 54% | 7% | 14 |
| 7 | TUMOR PROGRESSION LOCUS 2 | 8 | 100% | 3% | 5 |
| 8 | COT ONCOGENE | 6 | 71% | 3% | 5 |
| 9 | COT KINASE | 3 | 100% | 2% | 3 |
| 10 | COT PROTOONCOGENE | 3 | 100% | 2% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Tp12 kinase signal transduction in inflammation and cancer | 2011 | 28 | 80 | 75% |
| Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease | 2009 | 21 | 41 | 98% |
| Regulation and function of TPL-2, an I kappa B kinase-regulated MAP kinase kinase kinase | 2011 | 34 | 100 | 57% |
| I kappa B kinase regulation of the TPL-2/ERK MAPK pathway | 2012 | 28 | 118 | 47% |
| Coordinating TLR-activated signaling pathways in cells of the immune system | 2007 | 70 | 64 | 30% |
| TPL2 signalling: From Toll-like receptors-mediated ERK1/ERK2 activation to Cystic Fibrosis lung disease | 2014 | 1 | 51 | 57% |
| TPL-2/COT AND COX-2 IN BREAST CANCER | 2008 | 15 | 42 | 45% |
| Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer | 2015 | 0 | 142 | 57% |
| MAP kinase kinase kinases and innate immunity | 2006 | 64 | 81 | 16% |
| Macrophages in multiple myeloma: emerging concepts and therapeutic implications | 2013 | 3 | 137 | 15% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INFLAMMAT SIGNALING | 4 | 75% | 1.6% | 3 |
| 2 | TEAM MOL CELLULAR PHYSIOPATHOL OBES DIABET 7 | 1 | 50% | 1.0% | 2 |
| 3 | CLIN MED CHINESE WESTERN MED | 1 | 50% | 0.5% | 1 |
| 4 | GENOM METAB DIS | 1 | 50% | 0.5% | 1 |
| 5 | PROGRAM MOL BIOL BIOMED | 1 | 50% | 0.5% | 1 |
| 6 | PROT STRUCTURE | 1 | 50% | 0.5% | 1 |
| 7 | FOOD SCI BIOTECHNOL PROGRAM | 1 | 25% | 1.0% | 2 |
| 8 | CONSEJO SUPER INVEST CIENT MED | 0 | 33% | 0.5% | 1 |
| 9 | DRUG SAFETY METABOL | 0 | 33% | 0.5% | 1 |
| 10 | PROT PHOSPHORYLAT UNITMRC | 0 | 33% | 0.5% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000093032 | TAK1//TRAF4//TRAF5 |
| 2 | 0.0000081481 | I KAPPA B//IKK//C REL |
| 3 | 0.0000074086 | BATRACYLIN//2 LITHIOMETHYLPHENYL ISOCYANIDE//4H 3 1 BENZOXAZINES |
| 4 | 0.0000072108 | MK2//MAPKAP K2//MK5 |
| 5 | 0.0000070284 | A20//STRESS ASSOCIATED PROTEIN//ZINC FINGER PROTEIN A20 |
| 6 | 0.0000062567 | ERK5//MEK5//EXTRACELLULAR SIGNAL REGULATED KINASE 5 ERK5 |
| 7 | 0.0000061974 | TIR DOMAIN//PELLINO//INNATE IMMUN INFLAMMAT |
| 8 | 0.0000059769 | RAF//RAF 1//LEO JENKINS CANC |
| 9 | 0.0000058899 | PIM 2//PIM 1//PIM 3 |
| 10 | 0.0000048541 | JNK//MKK4//JNK3 |